European Cytokine Network
MENUBenefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer Volume 9, numéro 1, March 1998
Illustrations
P. Viens, D. Genre, C. Protière, G. Gravis, F. Bertucci, D. Cowen, J. Camerlo, C. Chabannon, G . Novakovitch, M. Conte, M. Finaud, J.P. Moatti and D. Maraninchi
- Mots-clés : breast cancer, cost efficiency, filgrastim, peripheral stem cells, sequential intensive chemotherapy.
- Page(s) : 93-8
- Année de parution : 1998
INTRODUCTION Dose intensification in chemotherapy is commonly used, based on encouraging results seen during the treatment of several of chemosensitive tumors such as malignant lymphomas [1-4], poor-risk breast cancers [5] and advanced stages of ovarian carcinomas [6, 7]. Chemotherapy dose intensification is supported by recombinant hematopoietic growth factors (HGFs), such as filgrastim (r-metHuG-CSF), alone or in combination [...]